• Non ci sono risultati.

Nuove prospettive

N/A
N/A
Info
Scarica
Protected

Academic year: 2022

Condividi "Nuove prospettive"

Copied!
44
0
0

Caricamento.... (Visualizza il testo completo ora)

Scarica adesso ( 44 pagine )

Testo completo

(1)

TUMORI GASTROINTESTINALI - NUOVE PROSPETTIVE -

Dr. Armando Orlandi

(2)

• Consensus molecular subtypes (CMS) in CRC

• CMS background

• CMS and FIRE-3/CALGB (ASCO17)

• CMS and MAX (ESMO17)

• Immunotherapy and GI cancer

• CMS1CMS4 and Immunotherapy strategies

• GEJ and Immunotherapy

• New drugs in Pancreatic cancer

• Eryaspase (phase II study)

• CPI-613 (phase I study)

OUTLINE

Tumori Gastrointestinali – Nuove Prospettive –

Roma, 7 ottobre 2017 Dr. Armando Orlandi

(3)

Consensus molecular subtypes (CMS) in CRC

• CMS background

• CMS and FIRE-3/CALGB (ASCO17)

• CMS and MAX (ESMO17)

• Immunotherapy and GI cancer

• CMS1CMS4 and Immunotherapy strategies

• GEJ and Immunotherapy

• New drugs in Pancreatic cancer

• Eryaspase (phase II study)

• CPI-613 (phase I study)

OUTLINE

Tumori Gastrointestinali – Nuove Prospettive –

Roma, 7 ottobre 2017 Dr. Armando Orlandi

(4)

Consensus molecular subtypes (CMS) in CRC

CMS background

(5)

Guinney J. et al, Nat Med 2015

Consensus molecular subtypes (CMS) in CRC

CMS background

(6)

Guinney J. et al, Nat Med 2015

CMS1 CMS2 CMS3 CMS4

Consensus molecular subtypes (CMS) in CRC

CMS background

(7)

Consensus molecular subtypes (CMS) in CRC

CMS and FIRE-3/CALGB (ASCO17)

(8)

Consensus molecular subtypes (CMS) in CRC

CMS and FIRE-3 (ASCO17)

(9)

Consensus molecular subtypes (CMS) in CRC

CMS and CALGB (ASCO17)

(10)

Consensus molecular subtypes (CMS) in CRC

CMS and FIRE-3(ASCO17)

(11)

Consensus molecular subtypes (CMS) in CRC

CMS and CALGB (ASCO17)

(12)

Consensus molecular subtypes (CMS) in CRC

CMS and FIRE-3 vs CALGB (ASCO17)

CMS1

CMS2

CMS3

CMS4

X

X

FIRE- 3

CALGB

(13)

Consensus molecular subtypes (CMS) in CRC

CMS and MAX trial (ESMO17)

(14)

Consensus molecular subtypes (CMS) in CRC

CMS and MAX trial (ESMO17)

(15)

J. Mooi et al. ESMO17

Consensus molecular subtypes (CMS) in CRC

CMS and MAX trial (ESMO17)

(16)

J. Mooi et al. ESMO17

Consensus molecular subtypes (CMS) in CRC

CMS and MAX trial (ESMO17)

(17)

J. Mooi et al. ESMO17

Consensus molecular subtypes (CMS) in CRC

CMS and MAX trial (ESMO17)

(18)

• Prognostic value of CMS in CRC.

• Different prognostic value of CMS in mCRC vs adjCRC.

• CMS1 best prognosis in adjCRC and worst prognosis in mCRC.

• CMS2 best prognosis in mCRC.

• Not clear predictive role of CMS for Cetuximab or Bevacizumab.

Consensus molecular subtypes (CMS) in CRC

CONCLUSION

(19)

• Consensus molecular subtypes (CMS) in CRC

• CMS background

• CMS and FIRE-3/CALGB (ASCO17)

• CMS and MAX (ESMO17)

Immunotherapy and GI cancer

CMS and Immunotherapy strategies

• GEJ and Immunotherapy

• New drugs in Pancreatic cancer

• Eryaspase (phase II study)

• CPI-613 (phase I study)

OUTLINE

Tumori Gastrointestinali – Nuove Prospettive –

Roma, 7 ottobre 2017 Dr. Armando Orlandi

(20)

Immunotherapy and GI cancer

CMS and Immunotherapy strategies

CMS4 Mesenchymal CMS1

MSI - Immune

CMS2 Canonical

CMS3 Metabolic

(21)

Immunotherapy and GI cancer

CMS and Immunotherapy strategies

(22)

D.T. Le et al. NEJM 2015

Immunotherapy and GI cancer

CMS1 and Immunotherapy strategies

Overman et al. Lancet 2017

(23)

D.T. Le et al. NEJM 2015

Immunotherapy and GI cancer

CMS1 and Immunotherapy strategies

Overman et al. Lancet 2017

(24)

Immunotherapy and GI cancer

CMS2-3-4 and Immunotherapy strategies

Strategy: PD1 blockade +MEK inhibitors or chemotherapy or TCBs?

(25)

Immunotherapy and GI cancer

CMS2-3 and Immunotherapy strategies

(26)

Immunotherapy and GI cancer

CMS2-3 and Immunotherapy strategies

(27)

Immunotherapy and GI cancer

CMS4 and Immunotherapy strategies

(28)

Immunotherapy and GI cancer

CMS4 and Immunotherapy strategies

(29)

• Consensus molecular subtypes (CMS) in CRC

• CMS background

• CMS and FIRE-3/CALGB (ASCO17)

• CMS and MAX (ESMO17)

Immunotherapy and GI cancer

• CMS and Immunotherapy strategies

GEJ and Immunotherapy

• New drugs in Pancreatic cancer

• Eryaspase (phase II study)

• CPI-613 (phase I study)

OUTLINE

Tumori Gastrointestinali – Nuove Prospettive –

Roma, 7 ottobre 2017 Dr. Armando Orlandi

(30)

Immunotherapy and GI cancer

GJE and Immunotherapy strategies

(31)

Immunotherapy and GI cancer

GJE and Immunotherapy strategies

Z. Wainberg et al., ESMO 2017

(32)

Z. Wainberg et al., ESMO 2017

Immunotherapy and GI cancer

GJE and Immunotherapy strategies

(33)

Z. Wainberg et al., ESMO 2017

Immunotherapy and GI cancer

GJE and Immunotherapy strategies

(34)

Z. Wainberg et al., ESMO 2017

Immunotherapy and GI cancer

GJE and Immunotherapy strategies

(35)

Z. Wainberg et al., ESMO 2017

Immunotherapy and GI cancer

GJE and Immunotherapy strategies

(36)

Z. Wainberg et al., ESMO 2017

Immunotherapy and GI cancer

GJE and Immunotherapy strategies

(37)

Z. Wainberg et al., ESMO 2017

Immunotherapy and GI cancer

GJE and Immunotherapy strategies

(38)

• Consensus molecular subtypes (CMS) in CRC

• CMS background

• CMS and FIRE-3/CALGB (ASCO17)

• CMS and MAX (ESMO17)

• Immunotherapy and GI cancer

• CMS1CMS4 and Immunotherapy strategies

• GEJ and Immunotherapy

New drugs in Pancreatic cancer

• Eryaspase (phase II study)

• CPI-613 (phase I study)

OUTLINE

Tumori Gastrointestinali – Nuove Prospettive –

Roma, 7 ottobre 2017 Dr. Armando Orlandi

(39)

Hammel et al. ESMO 2017

New drugs in Pancreatic cancer

A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma

(40)

Hammel et al. ESMO 2017

New drugs in Pancreatic cancer

A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma

(41)

New drugs in Pancreatic cancer

1733PD - New promising combination therapy of a mitochondrial metabolism inhibitor with mFOLFIRINOX in pancreatic cancer

(42)

New drugs in Pancreatic cancer

1733PD - New promising combination therapy of a mitochondrial metabolism inhibitor with mFOLFIRINOX in pancreatic cancer

(43)

• Interesting activity in phase 1 study of innovative combination.

• Confirmation in phase III study is warranted.

• New target therapy.

New drugs in Pancreatic cancer

1733PD - New promising combination therapy of a mitochondrial metabolism inhibitor with mFOLFIRINOX in pancreatic cancer

• Metabolic therapy ERA?

(44)

[email protected]

GRAZIE DELL’ATTENZIONE

Riferimenti

Scarica adesso ( PDF - 44 pagine - 2.40 MB )

Documenti correlati

Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy

In this study, we reported the case of a patient with non-small cell metastatic lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) who received gefitinib in

Therapy of breast cancer with molecular targeting agents.

Weekly paclitaxel (PTC) + trastuzumab (T) as first-line therapy of patients (PTS) with HER- 2/neu positive metastatic breast cancer (MBC): a multicenter random- ized phase II

Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)

Abstract Background: In a phase III trial in patients with metastatic pancreatic cancer (MPC), nab-paclitaxel plus gemcitabine (nab-P/Gem) demonstrated greater efficacy but higher

Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized Phase II

Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: Results from the ITACa randomized clinical trial

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with

Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer

Random- ized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1

Ogivri trastuzumab

Ogivri in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach

4 Cytotoxic Chemotherapy for Metastatic Colorectal Cancer

Two randomized phase III studies in patients with metastatic CRC provided the initial evidence that first-line combination therapy with irinotecan plus 5-FU/LV (IFL) resulted